Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults
Randomized, Placebo-Controlled, Dose-Escalating, Double-Blinded Phase 1 Safety and Immunogenicity Study of Clade C DNA Vaccine ADVAX e/g + ADVAX p/N-t (ADVAX) Administered Intramuscularly to HIV-Uninfected, Healthy Volunteers.
Sponsor: Aaron Diamond AIDS Research Center
A PHASE1 clinical study on HIV Infection, this trial is completed. The trial is conducted by Aaron Diamond AIDS Research Center and has accumulated 6 data snapshots since 2003. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Dec 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aaron Diamond AIDS Research Center
- International AIDS Vaccine Initiative
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .